Verix's patented Tovana™ platform and its full team join Trinity, extending TrinityEDGE™ from what commercial teams know into what they do next

Verix 的专利 Tovana™ 平台及其完整团队加入 Trinity，将 TrinityEDGE™ 从商业团队已知的领域延伸至其下一步行动。

WALTHAM, Mass.

马萨诸塞州沃尔瑟姆

,

，

Oct. 20, 2026

2026年10月20日

/PRNewswire/ -- Trinity, the leader in integrating human and artificial intelligence for life sciences commercialization, today announced it has acquired Verix, the pharma-native commercial intelligence company behind the patented, AI-powered Tovana™ platform. Tovana is live today in global pharma, biotech, and specialty pharma commercial organizations, where it turns prescription, claims, clinical, and engagement data into continuous next-best-action, dynamic targeting, and omnichannel orchestration for brand, field, and digital teams.

/美通社/ -- 生命科学商业化领域人机智能整合的领导者 Trinity 今日宣布，已收购 Verix。Verix 是一家源自制药行业的商业智能公司，其拥有专利且由人工智能驱动的 Tovana™ 平台备受瞩目。目前，Tovana 已在全球制药、生物科技及 specialty pharma（专科制药）商业组织中投入实际应用，帮助品牌团队、现场团队和数字团队将处方数据、理赔数据、临床数据和互动数据转化为持续的“下一步最佳行动”建议、动态目标定位以及全渠道协同编排。

The acquisition brings Verix's entire team into Trinity and adds an AI execution layer to TrinityEDGE. Terms were not disclosed..

此次收购将 Verix 的整个团队纳入 Trinity，并为 TrinityEDGE 增加了 AI 执行层。交易条款未予披露。

Why now

为何是现在

Pharma has already bought AI but has not yet realized the pay off. Trinity's 2025 Commercial and Medical IT benchmark found that 100 percent of surveyed organizations had adopted generative AI in some capacity, yet innovation confidence averaged just 3 out of 5, and every respondent described their organization as only somewhat prepared to respond rapidly to industry change.

制药行业已经投资了人工智能，但尚未实现回报。Trinity 2025年商业与医疗IT基准研究发现，100%的受访组织已在某种程度上采用了生成式人工智能，然而创新信心平均仅为3分（满分5分），且每位受访者都表示其组织仅在一定程度上做好了快速应对行业变化的准备。

A separate Trinity benchmark of new product planning and commercial strategy leaders found only 10 percent had a clear AI strategy they were scaling across workflows. Adoption is universal yet impact is not..

Trinity 针对新产品规划与商业战略领导者开展的一项独立基准研究发现，仅有 10% 的受访者拥有清晰的人工智能战略，并正在将其规模化应用于各项工作流程中。人工智能的采纳已普遍化，但其影响却尚未同步显现。

The reason is rarely the model. It is the distance between an insight and the moment someone acts on it. Targeting lists go stale between planning cycles. Omnichannel plans degrade. Next-best-action tools get ignored because reps cannot see why they should trust them. Brands pay twice, once for insight and again for a separate execution vendor, and still struggle to show impact.

问题很少出在模型本身，而在于从获得洞察到有人据此采取行动之间的时间差。目标客户名单在规划周期之间变得过时，全渠道计划效果衰减，下一步最佳行动工具因销售代表无法理解为何应信任它们而遭到忽视。品牌方为此支付双重费用：一次用于获取洞察，另一次用于单独的执行业务供应商，却仍难以彰显实际成效。

Closing that insight-to-action loop is the problem TrinityEDGE with Tovana will solve..

TrinityEDGE 与 Tovana 将解决的问题，正是打通从洞察到行动的闭环。

The acquisition also advances Trinity's growth strategy. Over the past three years Trinity has augmented its advisory and insights services with the TrinityEDGE productized commercialization platform, adding software, data, and AI alongside 1,500 professionals in 14 offices on five continents. Verix deepens Trinity's presence with the brand, field, and digital buyers who sit beyond its traditional strategy and insights relationships, and establishes a dedicated AI and product development center to build and ship commercial AI at scale..

此次收购也推动了 Trinity 的增长战略。在过去三年中，Trinity 通过推出 TrinityEDGE 产品化商业化平台，增强了其咨询与洞察服务，在五大洲的 14 个办公室中，除了拥有 1,500 名专业人士外，还增加了软件、数据和人工智能能力。Verix 帮助 Trinity 深化了与传统战略和洞察关系之外的品牌、实地和数字买家的联系，并建立了一个专门的人工智能和产品开发中心，以规模化构建和交付商业人工智能解决方案。

Proof, not promise

是证明，而非承诺

Tovana is not a new build. It has been developed and validated in live pharmaceutical and biotech deployments since 2007, across large global pharma, mid-size biotech, and specialty and rare disease organizations.

Tovana 并非全新构建的系统。自 2007 年以来，它已在大型全球制药企业、中型生物技术公司以及专注 specialty 和罕见病的组织中，经过实际制药和生物技术部署的开发与验证。

Deployed at scale in oncology and specialty markets.

在肿瘤学和专科市场大规模部署。

Tovana supports commercial teams at global pharmaceutical companies and emerging biotechs, including publicly referenced work and support for the U.S. launch of a targeted oncology immunotherapy in a market its sponsor estimates at more than $400 million.

Tovana 为全球制药公司和新兴生物技术企业的商业团队提供支持，包括公开案例以及在美国市场推出一款靶向肿瘤免疫疗法的支持工作，该疗法的发起方估计其市场规模超过4亿美元。

Measured commercial lift.

实测商业运力。

One of the largest pharmaceutical oncology divisions in the United States increased leading KPIs, including new prescriptions, by 15 to 25 percent with Tovana. A rare oncology therapy team improved field-facing NPS by 12x.. A medical device commercial team improved sales outcomes within three months of implementation..

美国最大的制药公司肿瘤部门之一通过与Tovana合作，将包括新处方在内的关键绩效指标提升了15%至25%。一个罕见肿瘤治疗团队将面向外部的净推荐值（NPS）提高了12倍。一个医疗器械商业团队在实施后的三个月内改善了销售业绩。

Time to value measured in weeks.

以周为单位衡量的价值实现时间。

Tovana's pharma-specific data foundation, automated data pipelines, and pre-built model toolkit mean clients adopt targeting and engagement models already proven in live deployments, with rapid configuration and deployment inside a single planning cycle.

Tovana 专为制药行业打造的数据基础、自动化数据流水线以及预构建的模型工具包，意味着客户能够采用已在实际部署中得到验证的目标定位与互动参与模型，并在单个规划周期内实现快速配置与部署。

What clients get

客户获得的内容

A plan that holds up between quarters.

一个在季度之间仍能保持有效的计划。

Targeting, segmentation, and channel mix update against what the market is actually doing, so the engagement plan approved in January is still the plan operating in June.

根据市场实际动态，更新目标定位、细分策略和渠道组合，因此1月批准的参与计划仍是6月正在执行的计划。

Guidance the field will actually use.

该字段实际使用的指南。

Recommendations arrive sourced and explainable, grounded in Trinity's therapeutic, launch, and benchmarking depth, and delivered inside the field workflow through FieldAdvisor. That is the difference between a next-best-action a rep follows and one a rep ignores.

推荐建议来源清晰、可解释，依托于Trinity在治疗领域、产品上市及基准对标方面的深厚积淀，并通过FieldAdvisor嵌入实地工作流程中交付。这正是代表会遵循的“下一步最佳行动”与会被其忽略的行动之间的区别所在。

One partner instead of two.

一个伴侣，而非两个。

Existing Trinity clients get a path from insight they already own to execution, without standing up another vendor or rebuilding integrations. Existing Verix clients keep the product, roadmap, and support they rely on, and gain Trinity's launch, market access, and competitive benchmarking context.

现有的 Trinity 客户能够利用其已拥有的洞察，直接打通至执行环节，无需引入新的供应商或重新构建集成。现有的 Verix 客户则可继续享有其所依赖的产品、路线图和支持服务，同时获得 Trinity 在发布、市场准入以及竞争基准对比方面的背景优势。

Tovana capabilities will be progressively integrated into the TrinityEDGE single sign-on environment over the coming months, strengthening CustomerEDGE™ execution, with the first joint offerings expected to reach clients in 1H 2027. Verix CEO Doron Aspitz joins Trinity's leadership team and will continue to guide the Tovana roadmap..

在未来几个月内，Tovana 的功能将逐步集成到 TrinityEDGE 单点登录环境中，从而增强 CustomerEDGE™ 的执行能力，预计首批联合解决方案将于 2027 年上半年交付给客户。Verix 首席执行官 Doron Aspitz 加入 Trinity 的领导团队，并将继续指导 Tovana 的产品路线图。

Leadership perspective

领导视角

'Every commercial leader I meet is asking how to put AI to work where it actually changes a call, a channel mix, or a forecast,' said Scott Evangelista, Chief Executive Officer of Trinity. 'Insight has outpaced execution. Teams are rich in disparate analysis and thin in decisive action in front of a customer.

“我遇到的每一位商业领导者都在询问，如何将人工智能应用于实际能够改变客户通话、渠道组合或预测的场景中，”Trinity 首席执行官 Scott Evangelista 表示，“洞察已超越执行。团队拥有大量分散的分析结果，但在面对客户时却缺乏果断的行动。”

Verix closes that gap. Next-best-action, dynamic targeting, and omnichannel orchestration now sit inside TrinityEDGE, proven in live pharma deployments and backed by 30 years of therapeutic and commercial judgment. That is what it means to lead in integrating human and artificial intelligence for life sciences commercialization.'.

Verix 弥合了这一差距。下一步最佳行动、动态定向以及全渠道编排现已集成于 TrinityEDGE 平台之中，该平台已在医药行业的实际部署中得到验证，并依托于三十年来在治疗与商业领域的专业判断。这正是我们在生命科学商业化进程中引领人类智能与人工智能融合的真谛所在。

'We built Verix on one conviction: commercial teams deserve intelligence that is timely, explainable, and usable in the flow of work,' said Doron Aspitz, Chief Executive Officer of Verix. 'Joining Trinity is the natural next step. Clients keep the product they rely on and gain the launch, access, and competitive context that tells them whether performance is genuinely competitive.

Verix 首席执行官多伦·阿斯皮茨表示：“我们基于一个信念构建了 Verix：商业团队应当获得及时、可解释且能融入工作流程的智能。加入 Trinity 是顺理成章的下一步。客户可以继续使用他们赖以信赖的产品，并获得发布、访问以及竞争背景信息，从而判断其表现是否真正具备竞争力。”

I am proud of what our teams have built and energized by what we can now build together.'.

我为我们团队所取得的成果感到自豪，并对我们今后能够携手共创的未来充满激情。

About Verix

关于 Verix

Verix is a leading provider of advanced commercial optimization solutions for the life sciences industry. Its flagship product, Tovana™, is a patented, AI-powered SaaS platform that enables life sciences companies to optimize commercial strategy and execution. Tovana integrates advanced machine learning, agentic workflows, and deep domain expertise into a single, intuitive platform, supporting dynamic targeting and segmentation, next best action, omnichannel orchestration, patient discovery, therapeutic landscape analysis, opportunity assessment, and bottom-up forecasting.

Verix 是生命科学行业先进商业优化解决方案的领先提供商。其旗舰产品 Tovana™ 是一个获得专利、由人工智能驱动的 SaaS 平台，旨在帮助生命科学公司优化商业战略与执行。Tovana 将先进的机器学习、智能体工作流以及深厚的领域专业知识整合到一个直观的统一平台中，支持动态目标定位与细分、下一步最佳行动、全渠道协同、患者发现、治疗格局分析、机会评估以及自下而上的预测。

Founded in 2007, Verix serves pharmaceutical, biotech, and specialty pharma commercial organizations from offices in the United States and Israel..

Verix成立于2007年，通过其位于美国和以色列的办公室，为制药、生物科技和专业制药领域的商业组织提供服务。

About Trinity

关于 Trinity

Trinity is a life sciences commercialization company that combines deep therapeutic, functional, and commercial expertise with AI-powered platforms. For more than 30 years, pharmaceutical, biotech, and medtech companies have relied on Trinity to connect strategy, data, and execution—supporting better decisions, more confident launches, and sustained commercial performance.

Trinity 是一家生命科学商业化公司，将深厚的治疗领域、职能运营及商业化专业知识与人工智能驱动的平台相结合。三十多年来，制药、生物技术和医疗科技公司一直依赖 Trinity 来连接战略、数据与执行，从而支持更优的决策、更有信心的产品上市以及可持续的商业表现。

Trinity helps clients turn insight into action and bring innovations to market with greater speed and confidence. Learn more at trinitylifesciences.com..

Trinity 帮助客户将洞察转化为行动，并以更快的速度和更强的信心将创新推向市场。更多信息请访问 trinitylifesciences.com。

SOURCE Trinity

来源：Trinity

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示